The national service framework for older people: England's approach to ending age discrimination in services and therapeutics

Drugs and Aging

Volumn 21, Issue 8, 2004, Pages 499-510

  Crome, Peter ^a,b   Natarajan, Indira ^b  

^a KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b N Staffordshire Comb Hlthcare N   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; FIBRINOLYTIC AGENT; GALANTAMINE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; LAXATIVE; MEMANTINE; NITRAZEPAM; NON PRESCRIPTION DRUG; NOOTROPIC AGENT; RIVASTIGMINE; SILDENAFIL; TRANQUILIZER; UNINDEXED DRUG; VITAMIN D; WARFARIN;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ATTITUDE; BIOLOGICAL MONITORING; CLINICAL TRIAL; DEMENTIA; DRUG COST; GOVERNMENT; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL PROFESSION; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; OSTEOPOROSIS; PATIENT REFERRAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACY; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SENESCENCE; STANDARDIZATION; STROKE; TOXICITY; VALIDATION PROCESS;

AGED; AGING; ATTITUDE OF HEALTH PERSONNEL; DRUG THERAPY; GOVERNMENT PROGRAMS; GREAT BRITAIN; HEALTH SERVICES FOR THE AGED; HUMANS; NATIONAL HEALTH PROGRAMS; PREJUDICE; PRESCRIPTIONS, DRUG;

EID: 3042739651     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421080-00002     Document Type: Review

References (59)

1. Department of Health. The NHS plan: a plan for investment: a plan for reform. London: Department of Health, 2000
2. Department of Health. The new NHS: modern dependable. London: Department of Health, 1997
3. Department of Health. National service framework for older people. London: Department of Health, 2001
4. Evans JG, Tallis R. A new beginning for care for elderly people? BMJ 2001; 322: 807-8
5. Ebrahim S. A new beginning for care for elderly people [letter]? BMJ 2001; 323: 337
6. Thompson S, Crome P. Intermediate care. Rev Clin Gerontol 2001; 11: 205-7
7. Department of Health. Medicines and older people: implementing the medicines-related aspects of the NSF for older people. London: Department of Health, 2001
8. Thompson S, Crome P. Appropriate prescribing in older people. Rev Clin Gerontol 2002; 12: 213-20
9. Fletcher AE, Jones DA, Bulpitt CJ, et al. The MRC trial of assessment and management of older people in the community: objectives, design and interventions [abstract]. BMC Health Serv Res 2002; 2: 21
10. Levenson R. Auditing age discrimination: a practical approach to promoting equality in health and social care. London: King's Fund, 2003
11. Department of Health. User guide for age discrimination bench marking tool [online]. Available from URL: http://www.publications.doh.gov.uk/nsf/ agediscrim.htm [Accessed 2004 May 7]
12. Royal College of Physicians of London. National clinical guidelines for stroke. London: Royal College of Physicians of London, 2000
13. Royal College of Physicians of Edinburgh. Consensus conference on stroke treatment and service delivery. Proc R Coll Physicians Edinb 2001; 31 Suppl. 8: 1-70
14. Royal College of Physicians of London. Osteoporosis: clinical guidelines for prevention and treatment. London: Royal College of Physicians, 1999
15. Royal College of Physicians. Osteoporosis and steroids. London: Royal College of Physicians of London, 2002
16. Department of Health. National service framework: coronary heart disease. London: Department of Health, 2000
17. Department of Health. National service framework: diabetes. London: Department of Health, 2001
18. Rudd AG, Lowe A, Hoffman P, et al. Effect of age on access to stroke care in England, Wales and Northern Ireland: results from the National Sentinel Audits of Stroke 1998-2002 [abstract]. Cerebrovasc Dis 2003; 16 Suppl. 4: 21
19. Fahey T, Montgomery AA, Barnes J, et al. Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study. BMJ 2003; 326: 580-3
20. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; I: 1349-54
21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3225-64
22. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 754-64
23. Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the very elderly trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18: 151-64
24. Stroke Prevention in Atrial Fibrillation Investigators. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1990; 21: 538: 45
25. Hart RG, Halperin JL, Pearce LA, et al., for the Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 2003; 138: 831-9
26. Crome P. What's different about older people. Toxicology 2003 Oct; 192 (1): 49-54
27. Crome P. Clinical trials in the elderly. Good Clin Pract J 2001 Sep; 8: 19-22
28. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. Note for guidance on studies in support of special populations: geriatrics [online] Available from URL: http://www.emea.eu.int/ pdfs/human/ich/ 037995en.pdf [Accessed 2004 May 7]
29. Stott DJ. Cardiovascular. In: Crome P, Ford G, editors. Drugs and the older population. London: Imperial College Press, 2000: 193-239
30. Chin-Dusting JPF, Dart AM. Age and treatment gap in the use of statins. Lancet 2003; 361: 1925-6
31. Shulman K, Rochon P, Sykora K, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ 2003; 326: 960-1
32. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's Disease: results of a US multicentre, randomised, double-blind, placebo controlled trial. The Donepezil Study Group. Neurology 1996; 7: 293-303
33. Greenblatt DJ, Allen MD. Toxicity of nitrazepan in the elderly: a report from the Boston collaborative Drug Surveillance Prgramme. Br J Clin Pharmacol 1978; 5: 407-13
34. Gaddie J, Legge JS, Palmer KNV, et al. Effect of nitrazepam in chronic obstructive bronchitis. BMJ 1972; 2: 688-9
35. Mossialos E, McKee M. Rationing treatment on the NHS: still a political issue. J R Soc Med 2003; 96: 372-3
36. Department of Health. The use of donepezil for Alzheimer's disease. Standing Medical Advisory Committee Advice (5/ 1998). London: Department of Health, 1998
37. National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence, 2001
38. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. The Donepezil MSAD Study Investigators Group. J Am Geriatr Soc 2003; 51: 737-44
39. AD2000 Collaborative Group. AD2000: a randomised double-blind trial of long-term donepezil treatment in 566 patients with Alzheimer's disease. Lancet. In press
40. Scottish Medicines Consortium. Memantine (Ebixa®): summary of recommendation (no. 57/03) [online]. Available from URL: http://www. scottishmedicines.org/updocs/memantine.pdf [Accessed 2004 May 7]
41. Media release: Alzheimer Scotland: 'surprised and disappointed' at the Scottish Medicines Consortium decision on the drug 'memantine' 2003 [online]. Available from URL: http:// www.alzscot.org/media/ebixadisappointment.html [Accessed 2004 Apr 14]
42. Alzheimer Scotland. Submission of evidence on memantine for the Scottish Medicines Consortium 2003 [online]. Available from URL: http://www.alzscot.org/ policy/memantine.html [Accessed 2004 Apr 14]
43. Aquilina C, Bullock R, Jones R, et al. Interim guidance on the use of memantine (Ebixa®) for Alzheimer's disease. London: Faculty for the Psychiatry of Old Age of the Royal College of Psychiatrists, 2003
44. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither, among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349-60.
45. Dudley NJ, Burns E. The influence of age on policies for admission and thrombolysis in coronary care units in the United Kingdom. Age Ageing 1992; 21: 95-8
46. Elder AT, Shaw TR, Turnbull CM, et al. Elderly and younger patients selected to undergo coronary artery angiography. BMJ 1991; 303: 950-3
47. Adams JN, Jamieson M, Rawles JM, et al. Women and myocardial infarction: agism rather than sexism? Br Heart J 1995; 73: 87-91
48. Dudley NJ, Bowling A, Bond M, et al. Age- and sex-related bias in the management of heart disease in a district general hospital. Age Ageing 2002; 31: 37-42
49. Shaw AB. Ensuring equity and quality of care for elderly people: a critique of the college report. J Roy Coll Physicians Lond 1995; 29: 89-91
50. Williams A. The rationing debate: rationing health care by age: the case for. BMJ 1997; 314: 820-5
51. Dornbrook-Lavender KA, Roth MT, Pieper JA. Secondary prevention of coronary heart disease in the elderly. Ann Pharmacother 2003; 37: 1867-76
52. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101: 2239-46
53. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial on interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
54. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
55. Winyard G. New drugs for multiple sclerosis: EL (95) 97. London: Department of Health, 1995
56. National Institute for Clinical Excellence. Beta interferon and glatiramer acetate in the treatment of multiple sclerosis. London: National Institute for Clinical Excellence, 2002
57. Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. Health Service circular 2002/004. Leeds: Department of Health, 2002
58. Department of Health. Flu and flu immunisation: key points and Q&A. London: Department of Health, 2001
59. Department of Health. The use of sildenafil in the treatment of erectile dysfunction. London: Department of Health, 1999